Molecular Data Inc.
Molecular Data Inc., through its subsidiaries, operates in the chemical e-commerce business in the People's Republic of China. The company operates technology-driven platform that connects participants along the chemical value chain through its integrated solutions. It delivers e-commerce solutions, financial solutions, warehousing and logistics solutions, and software-as-a-service suites for par… Read more
Molecular Data Inc. (MKDTY) - Total Assets
Latest total assets as of September 2021: $746.09 Million USD
Based on the latest financial reports, Molecular Data Inc. (MKDTY) holds total assets worth $746.09 Million USD as of September 2021.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Molecular Data Inc. - Total Assets Trend (2017–2020)
This chart illustrates how Molecular Data Inc.’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Molecular Data Inc. - Asset Composition Analysis
Current Asset Composition (December 2020)
Molecular Data Inc.'s total assets of $746.09 Million consist of 96.8% current assets and 3.2% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 1.7% |
| Accounts Receivable | $92.04 Million | 13.4% |
| Inventory | $2.82 Million | 0.4% |
| Property, Plant & Equipment | $4.92 Million | 0.7% |
| Intangible Assets | $536.00K | 0.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2020)
This chart illustrates how Molecular Data Inc.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Molecular Data Inc.'s current assets represent 96.8% of total assets in 2020, a decrease from 98.8% in 2017.
- Cash Position: Cash and equivalents constituted 1.7% of total assets in 2020, down from 10.1% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2017.
- Asset Diversification: The largest asset category is accounts receivable at 13.4% of total assets.
Molecular Data Inc. Competitors by Total Assets
Key competitors of Molecular Data Inc. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Renxin New Material Co. Ltd. A
SHE:301395
|
China | CN¥1.99 Billion |
|
Engro Corporation Ltd
KAR:ENGRO
|
Pakistan | PKRs765.68 Billion |
|
Fatima Fertilizer Company Ltd
KAR:FATIMA
|
Pakistan | PKRs256.23 Billion |
|
North Huajin Chemical Industries Co Ltd
SHE:000059
|
China | CN¥24.47 Billion |
|
Jiangsu Wujiang China Eastern Silk Market Co Ltd
SHE:000301
|
China | CN¥212.80 Billion |
|
Zangge Holding Co Ltd
SHE:000408
|
China | CN¥16.36 Billion |
|
Sichuan Jinlu Group Co Ltd
SHE:000510
|
China | CN¥2.53 Billion |
|
Jilin Gpro Titanium Industry Co Ltd
SHE:000545
|
China | CN¥2.48 Billion |
Molecular Data Inc. - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Strong asset utilization - Molecular Data Inc. generates 11.09x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Molecular Data Inc. is currently not profitable relative to its asset base.
Molecular Data Inc. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.10 | 0.96 | 1.44 |
| Quick Ratio | 1.09 | 0.95 | 1.41 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $68.27 Million | $ -29.42 Million | $ 112.28 Million |
Molecular Data Inc. - Advanced Valuation Insights
This section examines the relationship between Molecular Data Inc.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.00 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 84.3% |
| Total Assets | $684.82 Million |
| Market Capitalization | $2.44K USD |
Valuation Analysis
Below Book Valuation: The market values Molecular Data Inc.'s assets below their book value (0.00 x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Molecular Data Inc.'s assets grew by 84.3% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Molecular Data Inc. (2017–2020)
The table below shows the annual total assets of Molecular Data Inc. from 2017 to 2020.
| Year | Total Assets | Change |
|---|---|---|
| 2020-12-31 | $684.82 Million | +84.29% |
| 2019-12-31 | $371.60 Million | 0.00% |
| 2018-12-31 | $371.60 Million | -2.51% |
| 2017-12-31 | $381.15 Million | -- |